- Kazia Therapeutics ( KZIA ) is trading 53% higher before the bell after the company reported positive data from a phase I trial of its drug, paxalisib, in combination with radiotherapy for the treatment of brain metastases.
- U.S.-listed shares of KZIA added ~53% to $2.68 in premarket trading.
- The company said interim data from the first stage of the study showed that nine patients experienced complete or partial response, representing an overall response rate of 100%.
- A maximum tolerated dose of 45mg daily in combination with radiotherapy was confirmed during the trial.
- The company has begun patient enrollment to the expansion stage, with the objective of recruiting an additional 12 patients.
- During the trial, the patients comprised a range of primary tumours, with breast cancer the most common.
- About 200,000 cancer patients develop brain metastases in the United States each year, according to the company.
- KZIA stock is down 79% YTD.
For further details see:
Kazia Therapeutics surges 53% on positive data from phase 1 trial of brain cancer drug